Recombinant IL4 (Pascolizumab Biosimilar) antibody
Reactivity: Human
ELISA, BR, Func, InhA
Host: Human
Monoclonal
SB240683
unconjugated
Recombinant Antibody
-
- Target
- IL4 (Pascolizumab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Human
-
Host
-
Human
-
Clonality
- Monoclonal
-
Conjugate
- This IL4 (Pascolizumab Biosimilar) antibody is un-conjugated
- Application
- ELISA, Blocking Reagent (BR), Functional Studies (Func), Inhibition Assay (InhA)
- Purpose
- Anti-IL-4 [SB240683 (Pascolizumab, humanized 3B9)], Human IgG1, kappa
- Specificity
- This antibody binds human and cynomolgus monkey IL-4 and does not cross react with IL-4 from mouse, rat, cow, goat or horse. It does show binding to glycosylated interleukin-4. Interleukin-4 is a receptor for both interleukin 4 and interleukin 13. It couples to the JAK1/2/3-STAT6 pathway. The IL4 response is involved in promoting Th2 differentiation. The IL4/IL13 responses are involved in regulating IgE production and, chemokine and mucus production at sites of allergic inflammation. In certain cell types, can signal through activation of insulin receptor substrates, IRS1/IRS2.
- Cross-Reactivity
- Cynomolgus
- Characteristics
-
Original Species of Ab: Human
Original Format of Ab: IgG1
- Purification
- Protein A affinity purified
- Immunogen
- The original mouse antibody was generated by immunizing F1 hybrids of Balb/c and C57BL/6 mice with recombinant human IL-4 in Freunds complete adjuvant. The humanized version was generated by grafting CDRs of murine parent antibody onto human IgG1 kappa heavy- and light-chain frameworks.
- Clone
- SB240683
- Isotype
- IgG1 kappa
-
-
- Application Notes
- The original mouse version of this antibody can recognize recombinant human IL-4 in an ELISA and is also capable of inhibiting IL-4 dependent T-cell proliferation in vitro (PMID: 7517357). Binding of this humanized antibody completely blocks the binding of IL-4 to IL-4R. An in vitro study demonstrated that pascolizumab effectively neutralized IL-4 bioactivity in human cell lines including inhibited the proliferation of human T cells, human B cells and TF-1 cells, inhibition of interleukin-4-dependent IgE production by human PBMCs and up-regulation of Fc RII. It also inhibited the early events of asthma including TH2 cell differentiation, eosinophilia and IgE up-regulation. In vivo pharmacokinetic and chronic safety testing in cynomolgus monkeys demonstrated that pascolizumab was well tolerated without inducing adverse clinical responses (PMID:12296858). The pharmacokinetics of the human version of this antibody in the male Sprague Dawley rat was studied and the half life of the antibody was determined to be 11 days (US5914110A). A Phase I trial with a single intravenous dose in mild to moderate asthma demonstrated that it was well tolerated and had an elimination half-life of more than 2 weeks (Shames et al., 2001). However, a subsequent large-scale, multidose phase II trial in steroid-naive subjects with asthma was terminated because preliminary data showed that pascolizumab did not provide clinical benefit (clinical trials: NCT00024544).
- Restrictions
- For Research Use only
-
- Concentration
- 1 mg/mL
- Buffer
- PBS with 0.02 % Proclin 300.
- Preservative
- ProClin
- Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- 4 °C,-20 °C
- Storage Comment
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
- Target
- IL4 (Pascolizumab Biosimilar)
- Target Type
- Biosimilar
- Background
- IL4, BSF-1, Interleukin-4, B-cell stimulatory factor 1, Binetrakin, Lymphocyte stimulatory factor 1, Pitrakinra
- UniProt
- P05112
-
You are here:
